Schwaneck EC, et al. - Experts evaluated HBc-antibody-positivity prevalence and hepatitis B virus (HBV) reactivation incidence in 2,054 German rheumatology patients treated with immunosuppressants. Findings suggested significantly low median HBs antibody titer in the reactivation group. In patients with a history of HBV, biological disease-modifying antirheumatic drugs (bDMARDs) and conventional synthetic DMARD (csDMARDs) can be safely administered, if they are monitored closely. The risk of HBV reactivation is seen to increase with low titers of anti-HBs antibodies and a history of ≥ 3 classes of immunosuppressants. The reactivation group had more patients exposed to three or more classes of bDMARDs vs anti-HBc-positive patients without reactivation.